Outcomes of COVID‐19 in multiple myeloma patients treated with daratumumab

Author:

Jin Dian12ORCID,He Jingsong1345,Wu Wenjun1345,Han Xiaoyan1345,Le Jing2,Shu Wenxiu2,Fu Jiaping6,Kong Hongwei7,Wang Gang7,Zhou Xiujie8,Qu Zhigang9,Cai Zhen1345ORCID,He Donghua13459

Affiliation:

1. Bone Marrow Transplantation Center, The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou China

2. Department of Hematology Ningbo Medical Treatment Center Li Huili Hospital Ningbo China

3. Liangzhu Laboratory Zhejiang University Medical Center Hangzhou China

4. Institute of Hematology Zhejiang University Hangzhou China

5. Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy Hangzhou China

6. Department of Hematology Shaoxing People's Hospital Shaoxing China

7. Department of Hematology Quzhou People's Hospital Quzhou China

8. Department of Hematology Haining People's Hospital Haining China

9. Department of Hematology Yiwu Central Hospital Yiwu China

Abstract

AbstractDespite concerns about an increased risk of adverse outcomes following coronavirus disease (COVID‐19) in multiple myeloma patients treated with anti‐CD38 Abs, the impact of COVID‐19 on this group of patients is unclear. We tried to evaluate the clinical outcomes of these patients. We collected data from 1036 patients with multiple myeloma and enrolled 509 cases with COVID‐19. We divided enrolled patients into daratumumab or nondaratumumab cohorts based on whether they had received daratumumab‐based treatment within 6 months of COVID‐19 infection. We applied a propensity score matching method to reduce the bias of baseline characteristics, and then compared the incidence of adverse outcomes between these two cohorts. A total of 117 patients were enrolled in the daratumumab cohort, and 392 patients in the nondaratumumab cohort. After propensity score matching, 204 patients were matched. The proportions of patients who developed COVID‐19 pneumonia (59.8% vs. 34.3%, p < 0.001), were hospitalized (33.3% vs. 11.8%, p < 0.001) and developed severe disease (23.5% vs. 6.9%, p = 0.001) were higher in the matched daratumumab cohort. By multivariate analysis, daratumumab exposure was an independent risk factor for severe disease. An ECOG performance status >2 and history of chronic kidney disease were independent risk factors for COVID‐19‐related mortality among patients who received daratumumab‐based therapy. This study suggested that multiple myeloma patients exposed to daratumumab were at a higher risk of adverse outcomes from COVID‐19.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Zhejiang Province

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3